Pages that link to "Q33885648"
Jump to navigation
Jump to search
The following pages link to Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group (Q33885648):
Displaying 50 items.
- Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis (Q21134808) (← links)
- Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study (Q22000875) (← links)
- Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity (Q22306446) (← links)
- Adverse effects of biologics: a network meta-analysis and Cochrane overview (Q24234197) (← links)
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study (Q24630541) (← links)
- Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) (Q24631295) (← links)
- Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety (Q24673716) (← links)
- Safety of extended treatment with anakinra in patients with rheumatoid arthritis (Q24675209) (← links)
- Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study (Q24791246) (← links)
- Where is biological therapy going? (Q24792345) (← links)
- Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky (Q24793680) (← links)
- Interferon-beta for treatment of rheumatoid arthritis? (Q24793971) (← links)
- Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response (Q24799187) (← links)
- Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report (Q24799647) (← links)
- Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment (Q24800888) (← links)
- Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice (Q24801075) (← links)
- Behçet's disease (Q24804631) (← links)
- DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment (Q24812386) (← links)
- Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey (Q24816756) (← links)
- Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study (Q24816844) (← links)
- Biologic interventions for fatigue in rheumatoid arthritis (Q26471538) (← links)
- Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health (Q26749525) (← links)
- Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis (Q26750562) (← links)
- Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example (Q26766368) (← links)
- The interplay between inflammation and metabolism in rheumatoid arthritis (Q26785751) (← links)
- Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors (Q26824970) (← links)
- My treatment approach to rheumatoid arthritis (Q26829955) (← links)
- Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis (Q26852235) (← links)
- Phagocytosed Clofazimine Biocrystals Can Modulate Innate Immune Signaling by Inhibiting TNFα and Boosting IL-1RA Secretion (Q27301088) (← links)
- Selection of a Novel and Highly Specific Tumor Necrosis Factor (TNF ) Antagonist: INSIGHT FROM THE CRYSTAL STRUCTURE OF THE ANTAGONIST-TNF COMPLEX (Q27660024) (← links)
- X-ray structure of p38α bound to TAK-715: comparison with three classic inhibitors (Q27681911) (← links)
- Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities (Q27687777) (← links)
- Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analy (Q27694496) (← links)
- Updates on the risk factors for latent tuberculosis reactivation and their managements (Q28073158) (← links)
- What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis? (Q28074148) (← links)
- Therapeutic monoclonal antibodies (Q28137808) (← links)
- Tuberculosis: latency and reactivation (Q28201426) (← links)
- Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial (Q28214774) (← links)
- Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis (Q28243702) (← links)
- Adalimumab for the treatment of rheumatoid arthritis (Q28282655) (← links)
- Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china (Q28484306) (← links)
- Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis (Q28547851) (← links)
- A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients (Q28551075) (← links)
- Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis (Q28674280) (← links)
- The biological significance of evolution in autoimmune phenomena (Q28730944) (← links)
- Opinion: Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes (Q29393228) (← links)
- Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. (Q30234528) (← links)
- Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. (Q30235341) (← links)
- Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review. (Q30240229) (← links)
- Infliximab (Q30307998) (← links)